Novo Nordisk Stock (NVO): Wegovy Pill FDA Approval, CagriSema Filing, and the 2026 Outlook Investors Are Watching (Dec. 25, 2025)
December 25, 2025 — Christmas Day is a market holiday in the U.S., but Novo Nordisk A/S is still doing what it’s done for most of the past two years: pulling attention (and capital) toward anything labeled GLP‑1. NASDAQ Trader The headline catalyst is straightforward and extremely investable: the U.S. FDA has approved Novo Nordisk’s Wegovy pill, making it the first oral GLP‑1 treatment approved for chronic weight management in adults with obesity (or overweight with comorbidities). Reuters But the stock story is bigger than a single approval. Heading into 2026, Novo’s equity narrative is being rewritten around three questions: